RecruitingPhase 4NCT06479122

Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section

Efficacy of Intravenous Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen (Maxigesic®IV) in Multimodal Analgesia After Cesarean Section: a Randomized Controlled Trial


Sponsor

Seoul National University Hospital

Enrollment

84 participants

Start Date

Oct 9, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators aim to compare the analgesic efficacy of intravenous acetaminophen alone versus combination of acetaminophen/ibuprofen (Maxigesic®IV) in multimodal analgesia after cesarean section.


Eligibility

Sex: FEMALEMin Age: 19 Years

Inclusion Criteria2

  • Patients scheduled for elective cesarean section
  • Gestational age > 37+0 weeks

Exclusion Criteria11

  • Emergency cesarean section
  • Multiple pregnancy (e.g. twins, triplets)
  • Body weight < 50 kg
  • Preeclampsia
  • History of hypersensitivity to acetaminophen or ibuprofen
  • History of upper gastrointestinal tract bleeding or gastric ulcer
  • Underlying liver disease
  • Underlying kidney disease or GFR < 90 mL/min/1.73m2
  • Heart failure or severe hypertension
  • History of asthma
  • Chronic use of barbital or tricyclic antidepressants

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAcetaminophen

1g acetaminophen is administered during skin closure (end of operation).

DRUGAcetaminophen/Ibuprofen

A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)

DRUGAcetaminophen

1g acetaminophen is administered 6 hours after the first administration.

DRUGAcetaminophen/Ibuprofen

A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.


Locations(1)

Seoul National University Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06479122


Related Trials